LATS2 and liver cancer: Considering that mitochondrial malfunction might be a kind of therapeutic mechanism responsible for the sorafenib-based therapy in HCC, we wanted to determine whether modification of LATS2 could further enhance sorafenib-mediated liver cancer death via modulating mitophagy.